NFKB1 and Cognitive impairment: A previous chemical research study demonstrated that rosuvastatin was likely to be associated with lowering the risk of cognitive impairment through anti-inflammatory responses by inhibiting the activated nuclear factor kappa B (NF–kB) signaling pathway [48].